Eva Rustad de Brisis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eva Rustad de Brisis has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Anne-Marie Aas
Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
1 shared publication - Elin Bjørge Løken
Department of Nutrition, University of Oslo, P.O.Box 1046 Blindern, 0317, Oslo, Norway.
1 shared publication - Helga Refsum
Department of Pharmacology, University of Oxford, Oxford, UK
1 shared publication - Kirsti Bjerkan
Oslo University Hospital Aker
1 shared publication - Sofie F. Paus
Vestfold Hospital Trust
1 shared publication - Susanna E. Hanvold
Section of Nutrition and Dietetics, Department of Clinical Service, Division of Medicine, Oslo University Hospital, Oslo, Norway.
1 shared publication
Latest Publications
- 2 February 2015
- Published by Springer Nature in Obesity Surgery
- Vol. 25 (9) , 1672-1679
Great Health Benefits But No Change in Employment or Psychopharmaceutical Drug Use 2 Years After Roux-en-Y Gastric Bypass
The aim was to examine health benefits and lifestyle factors after Roux-en-Y gastric bypass (RYGB). Patients (n = 165) were investigated 2 years after RYGB in relation to psychopharmaceutical drugs, employment status, type 2 diabetes mellitus (T2DM), hypertension, metabolic syndrome (MetS), body weight, physical activity (PA), and energy intake. Excess weight loss (EWL) was 71.4 ± 20.6 %. Prevalence of T2DM, hypertension, and MetS was reduced (P < 0.001 for all). There were no changes in the use of psychopharmaceutical drugs (20.6 vs. 18.8 %, P = 0.549) or in the proportion of unemployed participants (37.7 vs. 33.3 %, P = 0.189) from pre- to post-surgery. Eighty-three percent achieved EWL ≥50 %. These subjects had a lower pre-surgery BMI. We found no differences in the prevalence of hypertension, T2DM, and MetS pre-surgery, but the prevalence was lower after surgery compared with subjects with EWL <50 %. RYGB induced remission of T2DM, hypertension, and MetS 2 years after surgery. The benefit was greatest in the group with EWL ≥50 %. Despite excellent weight loss, there was no change in the use of psychopharmaceutical drugs or proportion of unemployed participants.
- 2 February 2015
- Published by Springer Nature in Obesity Surgery
- Vol. 25 (9) , 1672-1679
Great Health Benefits But No Change in Employment or Psychopharmaceutical Drug Use 2 Years After Roux-en-Y Gastric Bypass
The aim was to examine health benefits and lifestyle factors after Roux-en-Y gastric bypass (RYGB). Patients (n = 165) were investigated 2 years after RYGB in relation to psychopharmaceutical drugs, employment status, type 2 diabetes mellitus (T2DM), hypertension, metabolic syndrome (MetS), body weight, physical activity (PA), and energy intake. Excess weight loss (EWL) was 71.4 ± 20.6 %. Prevalence of T2DM, hypertension, and MetS was reduced (P < 0.001 for all). There were no changes in the use of psychopharmaceutical drugs (20.6 vs. 18.8 %, P = 0.549) or in the proportion of unemployed participants (37.7 vs. 33.3 %, P = 0.189) from pre- to post-surgery. Eighty-three percent achieved EWL ≥50 %. These subjects had a lower pre-surgery BMI. We found no differences in the prevalence of hypertension, T2DM, and MetS pre-surgery, but the prevalence was lower after surgery compared with subjects with EWL <50 %. RYGB induced remission of T2DM, hypertension, and MetS 2 years after surgery. The benefit was greatest in the group with EWL ≥50 %. Despite excellent weight loss, there was no change in the use of psychopharmaceutical drugs or proportion of unemployed participants.